Ovid Therapeutc (OVID) Upgraded by Zacks Investment Research to Hold

Ovid Therapeutc (NASDAQ:OVID) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday.

According to Zacks, “Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological disorders. The company’s product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. It also involved in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid Therapeutics Inc. is based in New York, United States. “

Ovid Therapeutc (OVID) opened at 8.75 on Tuesday. The company has a 50-day moving average price of $8.70 and a 200-day moving average price of $10.04. Ovid Therapeutc has a one year low of $5.28 and a one year high of $15.93. The stock’s market cap is $215.26 million.

Ovid Therapeutc (NASDAQ:OVID) last posted its quarterly earnings data on Thursday, August 10th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.09). On average, analysts anticipate that Ovid Therapeutc will post ($3.88) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://ledgergazette.com/2017/10/17/ovid-therapeutc-ovid-upgraded-by-zacks-investment-research-to-hold.html.

In other Ovid Therapeutc news, CEO Jeremy M. Levin acquired 15,334 shares of the company’s stock in a transaction dated Friday, August 25th. The shares were acquired at an average cost of $7.15 per share, for a total transaction of $109,638.10. Following the completion of the purchase, the chief executive officer now owns 4,601,529 shares of the company’s stock, valued at approximately $32,900,932.35. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Institutional investors and hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp bought a new position in Ovid Therapeutc during the second quarter valued at about $135,000. TIAA CREF Investment Management LLC bought a new position in Ovid Therapeutc during the second quarter valued at about $142,000. Schwab Charles Investment Management Inc. bought a new position in Ovid Therapeutc during the second quarter valued at about $153,000. OxFORD Asset Management LLP bought a new position in Ovid Therapeutc during the second quarter valued at about $189,000. Finally, Citadel Advisors LLC bought a new position in Ovid Therapeutc during the second quarter valued at about $204,000. Hedge funds and other institutional investors own 32.44% of the company’s stock.

Ovid Therapeutc Company Profile

According to Zacks, “Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological disorders. The company’s product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. It also involved in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid Therapeutics Inc. is based in New York, United States. “

Ovid Therapeutc (OVID) opened at 8.75 on Tuesday. The company has a 50-day moving average price of $8.70 and a 200-day moving average price of $10.04. Ovid Therapeutc has a one year low of $5.28 and a one year high of $15.93. The stock’s market cap is $215.26 million.

Ovid Therapeutc (NASDAQ:OVID) last posted its quarterly earnings data on Thursday, August 10th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.09). On average, analysts anticipate that Ovid Therapeutc will post ($3.88) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://ledgergazette.com/2017/10/17/ovid-therapeutc-ovid-upgraded-by-zacks-investment-research-to-hold.html.

In other Ovid Therapeutc news, CEO Jeremy M. Levin acquired 15,334 shares of the company’s stock in a transaction dated Friday, August 25th. The shares were acquired at an average cost of $7.15 per share, for a total transaction of $109,638.10. Following the completion of the purchase, the chief executive officer now owns 4,601,529 shares of the company’s stock, valued at approximately $32,900,932.35. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Institutional investors and hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp bought a new position in Ovid Therapeutc during the second quarter valued at about $135,000. TIAA CREF Investment Management LLC bought a new position in Ovid Therapeutc during the second quarter valued at about $142,000. Schwab Charles Investment Management Inc. bought a new position in Ovid Therapeutc during the second quarter valued at about $153,000. OxFORD Asset Management LLP bought a new position in Ovid Therapeutc during the second quarter valued at about $189,000. Finally, Citadel Advisors LLC bought a new position in Ovid Therapeutc during the second quarter valued at about $204,000. Hedge funds and other institutional investors own 32.44% of the company’s stock.

Ovid Therapeutc Company Profile

Ovid Therapeutics Inc (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist.

Receive News & Ratings for Ovid Therapeutc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutc and related companies with MarketBeat.com's FREE daily email newsletter.